Serum Levels of miR-143 Predict Survival in Critically Ill Patients.
Journal
Disease markers
ISSN: 1875-8630
Titre abrégé: Dis Markers
Pays: United States
ID NLM: 8604127
Informations de publication
Date de publication:
2019
2019
Historique:
received:
23
03
2019
revised:
27
07
2019
accepted:
07
09
2019
entrez:
28
11
2019
pubmed:
28
11
2019
medline:
28
4
2020
Statut:
epublish
Résumé
Recent data suggested a potential role of miR-143 as a biomarker for systemic inflammation and infection. However, its role in critical illness and sepsis is only poorly understood. We determined circulating levels of miR-143 in 218 critically ill patients, of which 135 fulfilled sepsis criteria, and compared them to 76 healthy controls. Results were correlated with clinical records. In the total cohort of critically ill patients from a medical intensive care unit (ICU), miR-143 serum levels tended to be lower compared to healthy control samples, but this difference did not reach statistical significance. In ICU patients, serum levels of miR-143 were independent of disease etiology, including the presence of sepsis, or severity of disease. Importantly, low miR-143 serum levels were associated with an unfavorable short- and long-term prognosis in ICU patients. Our study identified different optimal cut-off values at which low miR-143 serum levels predicted mortality with a high diagnostic accuracy. In line with this, concentrations of circulating miR-143 correlated with markers of organ failure such as creatinine, bilirubin, or lactate in our cohort of critically ill patients. Low miR-143 serum levels are indicative for an unfavorable short- and long-term prognosis in critically ill patients admitted to a medical ICU. Our data suggest a previously unrecognized role for miR-143 measurements as a novel prognostic marker in critically ill patients.
Sections du résumé
BACKGROUND AND AIMS
OBJECTIVE
Recent data suggested a potential role of miR-143 as a biomarker for systemic inflammation and infection. However, its role in critical illness and sepsis is only poorly understood.
METHODS
METHODS
We determined circulating levels of miR-143 in 218 critically ill patients, of which 135 fulfilled sepsis criteria, and compared them to 76 healthy controls. Results were correlated with clinical records.
RESULTS
RESULTS
In the total cohort of critically ill patients from a medical intensive care unit (ICU), miR-143 serum levels tended to be lower compared to healthy control samples, but this difference did not reach statistical significance. In ICU patients, serum levels of miR-143 were independent of disease etiology, including the presence of sepsis, or severity of disease. Importantly, low miR-143 serum levels were associated with an unfavorable short- and long-term prognosis in ICU patients. Our study identified different optimal cut-off values at which low miR-143 serum levels predicted mortality with a high diagnostic accuracy. In line with this, concentrations of circulating miR-143 correlated with markers of organ failure such as creatinine, bilirubin, or lactate in our cohort of critically ill patients.
CONCLUSION
CONCLUSIONS
Low miR-143 serum levels are indicative for an unfavorable short- and long-term prognosis in critically ill patients admitted to a medical ICU. Our data suggest a previously unrecognized role for miR-143 measurements as a novel prognostic marker in critically ill patients.
Identifiants
pubmed: 31772686
doi: 10.1155/2019/4850472
pmc: PMC6854254
doi:
Substances chimiques
Biomarkers
0
MIRN143 microRNA, human
0
MicroRNAs
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
4850472Informations de copyright
Copyright © 2019 Christoph Roderburg et al.
Déclaration de conflit d'intérêts
The authors declare that in the past five years they have not received reimbursements, fees, funding, or salary from an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future, and that no such an organization is financing this manuscript. They do not hold any stocks or shares in an organization that may in any way gain or lose financially from the publication of this manuscript, either now or in the future. They do not hold or are not currently applying for any patents relating to the content of the manuscript. They have not received reimbursements, fees, funding, or salary from an organization that holds or has applied for patents relating to the content of the manuscript. They do not have any other financial competing interests.
Références
Anesthesiology. 2010 Apr;112(4):1023-40
pubmed: 20234303
PLoS One. 2009 Oct 12;4(10):e7405
pubmed: 19823581
Hepatology. 2011 Jan;53(1):209-18
pubmed: 20890893
Nat Rev Clin Oncol. 2014 Mar;11(3):145-56
pubmed: 24492836
Nat Genet. 2010 Jun;42(6):515-9
pubmed: 20453841
Gene. 2015 Apr 15;560(2):140-2
pubmed: 25637573
Int J Mol Sci. 2016 Jan 09;17(1):null
pubmed: 26761003
Dis Markers. 2015;2015:384208
pubmed: 25810564
Exp Mol Med. 2013 Sep 20;45:e42
pubmed: 24052167
Crit Care. 2011;15(1):R63
pubmed: 21324198
Mol Cancer Res. 2011 Jul;9(7):960-75
pubmed: 21653642
Liver Int. 2015 Apr;35(4):1172-84
pubmed: 25039534
Transl Oncol. 2010 Apr;3(2):109-13
pubmed: 20360935
PLoS One. 2013;8(1):e54612
pubmed: 23372743
Crit Care. 2010;14(1):R15
pubmed: 20144219
Biochem Biophys Res Commun. 2010 Mar 26;394(1):184-8
pubmed: 20188071
Oncotarget. 2017 Sep 16;8(48):84384-84395
pubmed: 29137432
Hum Mutat. 2012 Mar;33(3):551-60
pubmed: 22241525
Ann Emerg Med. 1999 Jan;33(1):85-91
pubmed: 9867892
Biochem Biophys Res Commun. 2009 Mar 13;380(3):437-41
pubmed: 19284987
Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4402-7
pubmed: 19246379
Clin Biochem. 2008 Aug;41(12):974-80
pubmed: 18538666
Front Immunol. 2017 Feb 16;8:118
pubmed: 28261201
PLoS One. 2016 Apr 28;11(4):e0153765
pubmed: 27124414
Vascul Pharmacol. 2019 Jan;112:24-30
pubmed: 30502421
J Crit Care. 2011 Apr;26(2):166-74
pubmed: 20869198
J Trauma Acute Care Surg. 2012 Oct;73(4):850-4
pubmed: 23026916
J Intern Med. 2012 Sep;272(3):243-6
pubmed: 22759240
Mol Med. 2018 Oct 17;24(1):54
pubmed: 30332984
Int J Mol Cell Med. 2017 Spring;6(2):77-86
pubmed: 28890884
Mediators Inflamm. 2010;2010:null
pubmed: 20871818
BMJ Open Gastroenterol. 2017 Sep 8;4(1):e000160
pubmed: 29177063
Crit Care Med. 2014 May;42(5):1096-104
pubmed: 24413579
Inflamm Bowel Dis. 2012 Jan;18(1):94-100
pubmed: 21557394
Arch Intern Med. 2011 Aug 8;171(15):1322-31
pubmed: 21824946
PLoS One. 2018 Oct 17;13(10):e0206064
pubmed: 30332461
Crit Care. 2010;14(3):R94
pubmed: 20500817
Int J Mol Sci. 2018 Jan 16;19(1):null
pubmed: 29337905
Crit Care. 2009;13(3):R95
pubmed: 19545363
J Int Med Res. 2016 Aug;44(4):875-81
pubmed: 27225861
Proc Natl Acad Sci U S A. 2008 Jul 29;105(30):10513-8
pubmed: 18663219
Nucleic Acids Res. 2014 Jul;42(12):7528-38
pubmed: 24875473
Crit Care. 2015 Jun 26;19:271
pubmed: 26111529
J Crit Care. 2013 Oct;28(5):882.e1-11
pubmed: 23337484
Semin Cancer Biol. 2008 Apr;18(2):131-40
pubmed: 18291670